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Abstract
Purpose Although practical and ethical constraints impose
special requirements for the evaluation of treatment safety
a n de f f i c a c yi nc h i l d r e n ,t h em a i ni s s u er e m a i n st h e
empirical basis for patient stratification and dose selection
at the early stage of the development of new chemical and
biological entities. The aim of this review is to highlight the
advantages and limitations of modelling and simulation
(M&S) in supporting decision making during paediatric
drug development.
Methods A literature search on Pubmed’s database Medical
Subject Headings (MeSH) has been performed to retrieve
relevant publications on the use of model-based approaches
in paediatric drug development and therapeutics.
Results M&S enable the assessment of the impact of
different regimens as well as of different populations on a
drug’s safety and efficacy profile. It has been widely used
in the last two decades to support pre-clinical and early
clinical drug development. In fact, M&S have been applied
to drug development as decision tools, as study optimiza-
tion tools and as data analysis tools. In particular, this
approach can be used to support dose adjustment in specific
subgroups of a population. M&S may therefore allow the
individualisation of drug therapy in children, improving the
risk–benefit ratio in this population.
Conclusions The lack of consensus on how to assess the
impact of developmental factors on pharmacokinetics,
pharmacodynamics, efficacy and safety has so far prevented
a broader use of M&S. This problem is compounded by the
limited collaboration between stakeholders, which prevents
data sharing in this field. In this article, we emphasise the
need for a concerted effort to promote the effective use of
this technology in paediatric drug development and avoid
unnecessary exposure of children to clinical trials.
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Introduction
Model-based drug development represents an invaluable
resource in pharmaceutical research and development [1].
The recent introduction of regulatory requirements for the
development of medicines for children will have a far-
reaching impact on how evidence can be generated on the
risk–benefit ratio of novel treatments for paediatric diseases.
These requirements make the application of model-based
approaches an obligatory step in paediatric drug develop-
ment. In this paper we show how modelling and simulation
(M&S) have been applied to drug development as decision
tools, as study optimisation tools and as data analysis tools.
These applications are split into three main sections, with
special focus on how these different domains can support drug
discovery, and non-clinical and clinical development. In
addition to the role of mechanistic models, which are surfacing
from research in systems biology and systems pharmacology,
and their contribution to the rationale for patient selection and
paediatric dosing regimen, practical and ethical limitations
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DOI 10.1007/s00228-010-0974-3imposedby empirical protocols are highlighted. The landscape
is then completed with an overview of the implications of
M&S for the advancement of the concept of personalised
medicines in children. Ultimately, this manuscript attempts to
emphasise the need for less empirical evidence and for a more
systematic, integrated evaluation of the overall risk–benefit
ratio of novel treatments in children.
Systems biology and systems pharmacology
The use of computer-aided mathematical simulations to
describe biological processes and systems is a fundamental
part of systems biology [2]. The objective of such
simulations is a model-based prediction of the behaviour
and the dynamics of biological systems. In this manuscript,
focus is placed on the role of modelling and simulation
(M&S) in systems pharmacology and paediatric diseases. In
this context, models can be used to quantitatively character-
ise how drugs affect the dynamics of biological systems as
well as the regulatory mechanisms triggered by a given
pharmacological intervention [3].
Because ofthe complexityofbiologicalsystems simplified
models are often used [4, 5]. However, the quality of model-
based predictions strongly depends on the quality of the
model, which in turn is defined by the quality of the data and
the profoundness of the knowledge it is based on. Whilst
simplified models have been particularly useful for interpret-
ing clinical data and developing novel biomarkers, complex
models may be required to predict the overall clinical
response or to quantify the role of modulating individual
pathways or targets in health and disease conditions.
These requirements have resulted into two different
approaches for the evaluation of the dynamics of biological
systems, namely a “bottom–up” and a “top–down” approach.
The “bottom–up” approach, historically used by biologists,
brings together all the known pieces at a subsystem level with
the objective of identifying a formal structure of the whole
system; a clear drawback is that it does not account for
possible unknown factors. In contrast, the “top–down”
approach departs from an observable and clinically relevant
behaviour and then iteratively identifies the biological
components, which could yield or cause such behaviour.
Both methods are complementary and have a wide range of
applications [6–9]. Despite the differences in the focus of
each approach, over the last few years, it has become clear
that to fully understand the complexity of biological
organisms they must be studied as whole systems; the
“top–down” approach seems to satisfy this requirement [2].
TheuseofM&Sindrugdevelopmenthascontributedtothe
advancementoftranslational research,allowingthe analysis of
complex biological systems and their interactions with
chemical and biological entities (i.e. drugs and biologics).
Thisfieldhasevolvedintowhatiscurrentlydefinedassystems
pharmacology. In conjunction with additional statistical con-
cepts, M&S has become a powerful tool for predicting drug
effects across a wide range of conditions, including extrapo-
lation from in vitro to in vivo, from animal to humans, from
health to disease, from short- to long-term effects.
Despite the increase in the use of M&S as tools for
decision-making in pharmaceutical R&D, their benefits as an
optimisation and data analysis tool has remained undervalued
and sometimes ignored by key stakeholders [10, 11]. This
attitude appears contradictory to ethical and scientific tenets,
which should underpin the evaluation of the risk–benefit
ratio in special populations, such as children. The ethical
constraints and practical limitations associated with clinical
research clearly impose new alternative methodology to
ensure accurate assessment of treatment response in these
patients. In that sense, the value of M&S to paediatric
research may be even greater than the evidence available so
far for drug development in adults. The interest in M&S is
also reaching the attention of the regulatory authorities. In
April 2008, the European Medicines Agency (EMA) organ-
ised a “Workshop on Modelling in Paediatric Medicines”
[12]. More recently, M&S have been proposed as a
framework for the evaluation of drugs by regulators taking
into account different clinical scenarios [7, 13].
Clinical research in paediatric diseases
As indicated previously, the purpose of the manuscript is to
evaluate the use of M&S as an alternative approach to the
design, analysis and interpretation of experiments and
clinical protocols in paediatric drug development. Despite
some limitations, M&S enable systematic, integrated
evaluation of drug and disease properties, providing
quantitative measures of treatment response across a wide
range of clinical and statistical designs, some of which
would not be feasible in real-life (i.e. due to exclusion
criteria). Furthermore, M&S can overcome many of the
pitfalls associated with the use of empirical protocols and
isolated, sequential developability criteria.
One of the greatest challenges in paediatric drug research is
to find the appropriate dosing regimen. It should be noted that
in spite of the ICH E11’s explicit requirement for appropriate
evaluation of medicinal products for children, today about
70% of the medicines given to the paediatric population and
93% of the medicines given to critically ill neonates remain
unlicensed or used off-label [14–16]. Even if a large number
of studies have been performed in paediatrics over the last
few decades, the empiricism upon which clinical drug
development is based often results in ineffective or unsafe
treatments. To ensure that appropriate dose rationale and
dosing regimens are used in paediatric trials, as well as
to identify potential subgroups of patients who may be
more susceptible to treatment response and/or adverse
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pharmacokinetic–pharmacodynamic (PKPD) relationships
[17, 18]. PK and PD properties may change in children
over the whole age continuum, and these changes must be
considered, especially when interpreting non-clinical safe-
ty pharmacology and toxicology data [14, 17, 18].
Understanding the effects of medicinal products in
paediatric patients is an important goal. However, this
should be done without compromising the well-being of
paediatric patients participating in clinical studies. This
responsibility is shared by companies, regulatory authori-
ties, health professionals and society as a whole [20]. It is
clear that traditional drug development approaches do not
satisfy the aforementioned requirement. In contrast, M&S
can be used to address various practical, scientific and
ethical issues that arise in paediatric research.
Empiricism in paediatric drug development
The majority of drugs on the market have been developed
primarily for adults [21]. Several constraints have been
used to justify the poor assessment of efficacy and safety in
the paediatric population, and consequently provide appro-
priate labelling recommendations for children. These con-
straints can be categorised into three classes, namely:
practical, ethical and regulatory.
Practical issues are principally the increasing cost of
clinical development and the availability of patients
required to satisfy the statistical power of each study
[22] (i.e. these criteria cannot be applied to paediatric patients
with rare diseases). Patient autonomy and unforeseen adverse
events represent some of the ethical factors that limit the
application of empirical experimental design in paediatric
drug research [15, 23]. These limitations constrain physi-
cians to extrapolate data from the adult population and to
normalise dosing regimens to a child’s body weight or
body surface area without evidence of linear correlations
for the changes in the parameters of interest across
populations (see examples in Table 1)[ 16, 24].
The FDA’s paediatric study decision tree is very clear in
recommending bridging and dose selection from adults to
children, and its purpose is to streamline the costs and time
required to develop drugs in the paediatric population [21].
The bridging rationale, and as such the data extrapolation,
can be justified only if the following conditions are all met.
Adults and children have to present:
1. The same disease progression
2. Similar PKPD relationships
3. Similar endpoints
If these requirements are not met, further PKPD or
efficacy studies are needed. We anticipate that M&S
methodology can result in important improvement in the
planning, implementation and analysis of such studies
[7]. In fact, the ICH E11 already proposes the use of
population PK analysis in paediatric studies in order to
facilitate the protocol design and to reduce practical and
ethical constraints [20].
From a regulatory perspective, lack of working knowl-
edge and understanding of M&S concepts create an
additional hurdle to the effective use and implementation
of the approach in regulatory submissions. Despite the
opportunities for the use of M&S by regulatory guidelines,
empiricism still plays a main role in drug development. As
recently shown by our group, a keyword-based search
performed on 95 European Public Assessment Reports
(1995–2007) reveals that only 22 out of the 95 documents
analysed refer to the use of M&S methodologies. Further-
more, these EPARS do not include keywords, such as
biosimulation, PKPD modelling or clinical trial simulation.
Modelling and simulation
In addition to the insight into the underlying pharmacolog-
ical mechanisms and dynamics of a biological system,
M&S also enable the assessment of important statistical
elements. The integration of these elements is currently
known as pharmacometrics. In pharmacometric research,
three important components are characterised, namely: a
drug model, a disease/placebo model and the implementa-
tion model (trial design and decision criteria). Whilst
modelling enables translation of the relevant features of a
system into mathematical language (i.e. model parameters),
simulation allows the assessment of a system’s performance
under hypothetical and real-life scenarios (i.e. “what-if”
scenarios), yielding information about the implication of
different experimental designs and quantitative predictions
about treatment outcome, dosing requirements and cova-
riate effects (Fig. 1)[ 7, 24, 25].
In this regard, the great advantage of the use of M&S in
paediatric drug development is the possibility of exploring
relevant scenarios before enrolling children into a clinical
protocol.Simulationsallowevaluationofarangeofparameter
values (dose, clearance, etc.), including an assessment of
criticalscenarios,suchasoverdosing,thatcannotbegenerated
in real-life studies [15]. Most importantly, it enables
systematic assessment of the impact of uncertainty.
Modelling andsimulation canbe usednot onlyasa learning
anddecision-makingtool,butalsoasadesignoptimisationand
data analysis tool. Consequently, it cansupportthe selection of
candidate drugs and streamline decisions regarding first-time
human, PKPD and safety/efficacy clinical studies [7, 24, 26].
Furthermore, great attention is being paid to study design
before the implementation of an experiment or clinical
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a new drug from the first steps in discovery to the approval
stage. Later in therapeutics and clinical practice, M&S can
guide dose adjustment for specific subgroups of a population
and enable the evaluation of the implications of relevant
factors, such as treatment adherence, changes in formulation
and drug combinations [22, 27].
Like all sciences, best practices should be followed when
performing M&S. To fulfil this objective the following
issues must be clearly defined a priori:
1. The objective(s) of the M&S exercise
2. The criteria for data selection and the exclusions or
limitations of the dataset
Fig. 1 Simulations allow the assessment of a system’s performance
under hypothetical and real-life scenarios (i.e. “what-if” scenarios),
yielding information about the implications of different experimental
designs and quantitative predictions about treatment outcome. In this
example, a model of haematopoiesis is used to simulate the effects of
darbepoetin alfa administered every 2 weeks in chemotherapy-induced
anaemia based on weight-based fixed-dosing regimens. Adapted from
Jumbe et al. [25]
Table 1 Examples of drugs commonly used in paediatric medicine for which the paediatric dose is not linearly correlated with body weight.
Details on the clinical implication of non-linearity between drug exposure and descriptors of body size can be found in Cella et al. [18]
Drug Therapeutic
indication
Adult dose Paediatric dose
Chloramphenicol Bacterial infection 50 mg/kg/day 50 mg/kg/day; neonates: 25 mg/kg/day
Carbamazepine Epilepsy 5–8 mg/kg every 12 h > 12 years: 5–8 mg/kg every 12 h; children: 3–10 mg/kg every 8 h;
infants: 3–10 mg/kg every 8 h
Phenytoin Epilepsy 2 mg/kg every 12 h Children: 2.3–2.6 mg/kg every 8 h; infants: 2.3 mg/kg every 8 h;
neonates: 2.5–4.0 mg/kg every 12 h
Propofol Anaesthesia < 55 years: 6–12 mg/kg/h;
>55 years: 3–6 mg/kg/h
2 months to 16 years: 7.5–18 mg/kg/h
Busulfan Cancer 0.8 mg/kg every 6 h ≤ 12 kg: 1.1 mg/kg every 6 h;>12 kg: 0.8 mg/kg every 6 h
Tobramycin Bacterial infection 3 mg/kg/day Children: 6 to 7.5 mg/kg/day;<2 weeks: 4 mg/kg/day; with
cystic fibrosis: 10 mg/kg/day
Enfuvirtide HIV 180 mg/day 11–15.5 kg: 54 mg/day; 15.6–20 kg: 72 mg/day; 20.1–24.5 kg:
90 mg/day; 24.6–29 kg: 108 mg/day; 29.1–33.5 kg: 126 mg/day;
33.6–38 kg: 144 mg/day; 38.1-42.5 kg: 162 mg/day
Oseltamivir Influenza 150 mg/day < 15 kg: 60 mg/day; 15-23 kg: 90 mg/day; 23-40 kg: 120 mg/day
Nelfinavir HIV 2.5 g/day 7.5–8.5 kg: 0.8 g/day; 8.5–10.5 kg: 1 g/day; 10.5–12 kg: 1.2 g/day;
12–14 kg: 1.4 g/day; 14–16 kg: 1.6 g/day; 16–18 kg: 1.8 g/day;
18-22 kg: 2.1 g/day
Digoxin Heart failure 1.4–4.0 μg/kg/day Children: 3–8 μg/kg/day; infants: 7.5–12 μg/kg/day; neonates:
4–8 μg/kg/day
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4. The statistical method, algorithm and methodology
5. Model qualification or validation criteria
It should be noted that the workflow and tools should
have an audit trail and be validated to ensure reproducibility
of the findings [7, 27]. The advantages and drawbacks of
model-based approaches from drug discovery to the clinical
practice will be highlighted in the following paragraphs.
M&S in drug discovery
During lead optimisation and candidate selection go/no-go
decisions have to be made. From the very first step of
development of an new molecular entity (NME), absorp-
tion, distribution, metabolism and elimination (ADME)
information is required to understand the drug’s properties
in vivo [28, 29]. The application of M&S methodologies at
this stage will support and facilitate decision-making
processes. Predictive models assist the selection of appro-
priate candidates, as well as the design of in vivo PK studies
[30]. The obvious advantage of this application is the
possibility of integrating in vitro to in vivo properties as
well as to pharmacodynamic characteristics, identifying
differences in drug performance in vivo, as opposed to
decision-making based on isolated developability criteria.
This concept has been recently applied in the evaluation of
COX2 inhibitors [31]. Furthermore, M&S allow optimisa-
tion of experimental protocols.
At this stage, pharmacokinetics can also be evaluated by
studying each part of the ADME process in an integrated
manner. Physiologically-based pharmacokinetic (PBPK)
models provide an integrated view of drug disposition in
vivo [28]. In contrast to empirical compartmental models, a
PBPK model is aimed at describing the in vivo behaviour of
the drug before the acquisition of in vivo data. PBPK relies
primarily on describing drug disposition in terms of organ
distribution, blood flow and metabolic capacity (Fig. 2).
This allows better understanding of PK properties, more
rational candidate selection, and extrapolation of dose
levels, of routes of administration, and of data across
species. This approach has some appealing features in that
predictions can be made about the need for changes in
dosing regimen because of developmental and other age-
related factors [7, 28, 30].
The relevance ofthistypeofinformation isevident already
at the lead optimisation stage: better and quicker understand-
ingof a drug’sP Kp r o f i l ein vivo may drastically improve
the decision-making process. Nevertheless, it is worth
highlighting that the predictive value of these models
depends on the selection of correct model parameterisation
and on the availability of suitable descriptors (i.e. experimen-
tal data reflecting the appropriate set of physicochemical
properties) [29].
M&S in non-clinical drug development
At the non-clinical phase in vitro and in vivo animal studies
are the main source of information about pharmacokinetic
and pharmacodynamic properties. The objective at this
stage is to further improve the understanding of the drug
properties in vivo and to extrapolate findings, identifying
correlations or making predictions about a drug’s perfor-
mance in humans (i.e. clinical response).
Juvenile toxicological studies, which involve young
animals, have been used to investigate a drug’s pharmacol-
ogy and toxicology. Findings are extrapolated assuming a
correlation between developmental growth in animals and
children [32]. Even if the assumptions and rationale can be
supported for some indications, numerous issues have to be
addressed to allow appropriate interpretation of the find-
ings. In contrast, M&S can optimise the use and interpre-
tation of those data, enabling a mechanism-based,
systematic extrapolation of the data across species (e.g.
scaling exposure findings for differences in metabolic
clearance). Furthermore, it allows quantitative assessment
of age- or growth-related differences in drug effects and
consequently the potential implications for different paedi-
atric age groups [19, 21].
In addition, the techniques available at this stage, such as
PBPK and PBPK-PD models [26], can use in vitro data to
predict plasma and tissue concentrations [33]. This implies
substantial reduction in the number of animals per experiment
and sometimes the replacement of animals by in silico
experiments. Also in this case, the use of a model-based
approach allows optimisation of experimental protocols,
improving the accuracy and efficiency of data extrapolation.
In summary, the benefits from M&S methodologies at
the non-clinical stage include the prediction and character-
isation of primary PK parameters (PBPK models) and
pharmacodynamic properties (PBPK-PD models). Model
parameters can then be used to predict the dose range to be
tested in clinical studies, including the requirements for
optimal sampling and study design [7, 26, 27].
M&S in clinical drug development
Limited availability of patients and practical constraints,
such as difficulties in blood sampling, have often been used
as justification for the lack of systematic evaluation of drug
response in children [14–16]. M&S can address many of
these limitations, but its wide implementation in clinical
development has remained wishful thinking. This is partly
due to the lack of understanding and working knowledge in
quantitative pharmacology and pharmacometrics by spon-
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cians, statisticians, research nurses) who are responsible for
the planning, design and/or approval of clinical trials.
PBPK and disease models
The difficulties in performing paediatric trials constrain
physicians in extrapolating data from the adult population
to children. For this purpose, simple allometric methods
based on body weight or body surface area have been
frequently used. However, particularly in neonates and
infants, the use of the allometric approach may fail to
identify the appropriate dosing range [16, 21]. Once more
PBPK models may play a pivotal role in the estimation of
dosing requirements across the paediatric population.
Physiological differences between adults and children and
between different age groups can be incorporated into the
model to evaluate variation in pharmacokinetics. This may
allow conversion of the exploratory nature of first-in
children studies into a confirmatory step [21].
Application of bridging techniques requires however
further understanding of disease. Therefore, disease and
disease progression models need to be considered when
comparing drug response and kinetics in adults and children
[7]. Disease models can also be applied to simulate
treatment response. In combination with drug models, it is
possible to explore the implications of different algorithms
for dose adjustment [7]. The use of disease models to
evaluate drug–disease interactions and the role of covariates
in pharmacokinetics, pharmacodynamics and treatment
outcome demand the use of somewhat sophisticated
statistical methods, which cannot be achieved by standard
linear regression techniques. These methods often rely upon
Bayesian statistical concepts and include parameterisation
based on hierarchical, non-linear mixed effects models, also
known as the population approach.
Fig. 2 Physiologically-based
pharmacokinetic (PBPK)
models provide an integrated
view of drug disposition in vivo.
In contrast to empirical com-
partmental models, a PBPK
model is aimed at describing the
in vivo behaviour of the drug
before the acquisition of in vivo
data. PBPK relies primarily on
describing drug disposition in
terms of organ distribution,
blood flow and metabolic
capacity. Actual experiments
become confirmatory and can
therefore be optimised in terms
of dose range, sample size,
frequency and sampling
intervals. Diagram adapted from
Theil et al [28]
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Population methods consider the population rather than the
individual as the object of the investigation. The approach is
particularly suitable when information on individual subjects is
limited (i.e. sparse sampling). In fact, this is a common situation
in pharmacokinetic and pharmacodynamic studies in children.
Hence, it would be already possible to circumvent the
aforementioned practical and ethical issues in paediatric
research [14, 34]. It is unfortunate that the expertise is still
limited to allow its widespread use in drug development.
Conceptually, population models rely on pooled data across
treatment cohorts or even across different studies [15], which
is of great importance considering that the number of
paediatric patients in some diseases may be extremely limited.
Moreover, one can evaluate different clinical scenarios without
exposing children to any risk, and explore drug, disease or
covariate effects in a larger number of virtual patients
compared with what is observed in the patients enrolled in a
real trial [15, 35]. A further advantage is the possibility of
assessing the clinical relevance of covariates to drug exposure
and to evaluate simultaneously their effect on the treatment
response [34]. As an example, Knibbe et al. recently reported
a population pharmacokinetic model to describe propofol
d i s p o s i t i o ni nc h i l d r e na g e d1t o5y e a r s .I nc o n t r a s tt ow h a t
happens in adults, the model showed the body weight to be a
covariate for clearance [36].
Populationpharmacokinetic(popPK)andpharmacokinetic-
pharmacodynamic (pop PKPD) models basically comprise
the representation of three main components: a structural
model that describes pharmacokinetics or pharmacodynamic
characteristics (e.g. two-compartment disposition, sigmoid
Emax); a statistical model describing between-subject vari-
ability and an error model that accounts for the residual
variability. Most importantly, population models incorporate
the effect of influential covariates (e.g. weight, age, pharma-
cogenetics etc.) [7, 14, 15] on model parameters (e.g. CL,
EC50), instead of correlating them directly with the observed
variables. This is particularly appealing, as it prevents the
bias common to empirical methods aimed at the assessment
of covariate effects in the presence of non-linear pharmaco-
kinetics and complex PKPD relationships [27]. This concept
is clearly illustrated by Ihmsen et al., who applied a PKPD
model to characterise the delayed onset and prolonged
recovery to rocuronium. The authors show the impact of
disease on drug potency when comparing healthy subjects
with patients affected by Duchenne muscular dystrophy [37].
Another concept introduced into paediatric research is
the KPD model. This represents a specific group of non-
linear mixed effect models that have been developed to
describe exposure–effect relationships in the absence of
drug concentration measurements [7, 38]. This approach is
very useful if drug elimination from the biophase is the
rate-limiting step in drug disposition [38]. The approach is,
however, not suitable for extrapolating data across different
scenarios (e.g. different doses, or populations) for which no
observations are available [7].
The availability of population PK and PKPD models offers
animportant opportunityasastudyoptimisationtool (e.g.dose
selection, sampling times, treatment duration and population
size). These models can also be used to support prediction and
extrapolation of data across different age-groups, dosing
regimens and formulations or delivery forms (Fig. 3)[ 7, 14,
26, 27, 39]. Moreover, population models may enable
extrapolation of long-term efficacy and safety based on
short-term pharmacokinetic and treatment response data.
M&S and biomarkers
A biologicalmarkerorbiomarker isdefinedasa characteristic
that is objectively measured and evaluated as an indicator of
normalbiologicalorpathogenicprocessesorpharmacological
responses to a therapeutic intervention [31, 40]. Biomarkers
can be directly measured or derived by model-based
approaches and expressed as model parameters. In drug
discovery and drug development a validated biomarker may
facilitate decision-making, supporting the prediction of
treatment response as well as guide dose adjustment. If
validated accordingly for sensitivity, specificity and clinical
relevance, biomarkers can also be used as surrogate
endpoints (symptoms or signs that constitute one of the
target outcomes). In this context, model-based analysis of
biomarker data can contribute to validation procedures and
enable comprehensive sensitivity analysis, with a clear
understanding of the sensitivity and specificity rates (i.e.
false-positive and false-negative rates). The availability of
biomarkers may also be a determinant in the progression of a
clinical trial when the clinical outcome is delayed or difficult
to quantify in short-term studies [31, 40].
Another important advantage of model-based approaches is
that they allow access to functional components and structures
of a biological system that cannot be identified experimentally.
The best example of such a concept is the quantification of
insulin sensitivity, as defined by the insulin sensitivity index.
The loss in insulin sensitivity because of diabetes progression
cannot be measured direct from insulin and glucose levels in
plasma; it is derived from a model. In addition, M&S provide
insight into how drug treatments may alter disease [41, 42].
Clinical trial simulation
In contrast to meta-analysis, clinical trial simulation (CTS)
enables the assessment of the impact of a range of design
characteristics on the statistical power to detect a treatment
effect prior to exposing patients to an experimental drug. In
a field where most clinical trials have a conservative design,
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innovative designs. Rather than performing power calcu-
lations that only take sample size and endpoint variability
into account, CTS allows calculation of power taking into
account a multitude of other factors.
In general, CTS utilises two types of models [43]. First, a
drug–action (PKPD) model is considered, which comprises
pharmacokinetic and pharmacodynamic factors. In chronic
diseases the model also accounts for disease progression.
Unfortunately, the lack of knowledge about the mechanisms
underlying treatment response in many therapeutic indications
has prevented the development of mechanistic PKPD models.
Hence, examples often refer to standard statistical models,
such as e.g. the mixed model for repeated measures
(MMRM). Such statistical models have however a downside
in that they often do not incorporate concentration–effect
relationships and therefore do not allow for inferences about
age-related differences in pharm a c o k i n e t i c s ,a si st h ec a s ef o r
paediatric populations. Second, CTS requires a trial execution
model. These models simulate other important aspects of the
trial, such as dropout, compliance and protocol deviations
(Fig. 4)[ 44]. In this manner, one can determine all possible
outcomes under candidate trial designs, allowing such trial
designs to be compared in a strictly quantitative manner. Thus
far, very few examples exist in which relevant design factors
have been evaluated prospectively as part of the planning of a
paediatric trial.
It is also important to stress that CTS allows investigation of
factors that cannot be scrutinised by meta-analysis or empirical
design. First, designs which have not been implemented cannot
Fig. 3 Modelling and simulation can be used to support prediction
and extrapolation of data in early clinical development. The graphs
show the implications of pharmacokinetic differences for systemic
exposure across different age groups in children. Based on pharma-
cokinetic parameter estimates systemic exposure can be simulated
for a range of dosing regimens. Note the non-linearity in the dose
range for the different age groups. Lines depict the fraction of
patients categorised by body weight reaching target exposure criteria
(a=AUC>6.02 mg*h/L, b=plasma concentrations above IC80 for at
least 3 h) following different doses of abacavir. circles10 kg, crosses
20 kg, triangles30 kg, squares40 kg. From Cella et al [10]
Fig. 4 The diagram depicts the major components of a clinical trial
simulation (CTS). In model-based drug development, a CTS can be
used to characterise the interactions between drug and disease, enabling
among other things the assessment of disease-modifying effects, dose
selection and covariate effects (e.g. age, body weight). In conjunction
with a trial model, CTS allows the evaluation of such interactions,
taking into account uncertainty and trial design factors, including the
implications of different statistical methods for the analysis of the data
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the influence of multiple design factors, whereas CTS allows
evaluation of a single factor at a time. Although meta-analyses
may provide valuable information about differences in patient
populations and treatment response, it is unfortunate that many
investigators consider overall publication review sufficient to
gather evidence on the role of design factors, as often suggested
in the discussion of meta-analysis results.
If simulated data is to be exchangeable with actual
patient data, it is imperative that not only model parameters
are unbiased, but that estimates of variability are also
accurate. Often interpretation of statistical model results
focuses on the predicted values of the treatment effect. This
does not necessarily mean that response distributions reflect
what occurs in the true patient population. In fact, it is not
infrequent to see model mis-specifications being corrected
by inflated estimates of variability. It is therefore critical for
clinicians to understand that standard goodness-of-fit
criteria do not take simulation characteristics into account
and may therefore not be indicative of the best model. Such
a comparison between simulated and original data can be
performed using graphical and statistical tools.
CTS relies on the availability of accurate model parameter
and corresponding distributions to investigate “what if”
scenarios across a different range of conditions or design
features, such as population size, stratification levels, dose
range, sampling scheme, and even different endpoints. One of
the main advantages of such a virtual or statistical experiment
is the possibility to predict ‘trial performance’ and so to
identify potential limitations in study and protocol design
prior to its implementation [7, 24, 45, 46]. In fact, some
clinical trial simulations have been evaluated against out-
comes from real trials. They showed accuracy and an
important correspondence between simulated and “real”
results [27]. For instance, Nguyen et al. have developed
a new dosing regimen for busulfan in infants, children
and adolescents through the use of population PK model.
The new regimen has been accepted and adopted as
conditioning treatment prior to haematopoietic stem-cell
transplantation in paediatric patients since 2005 [47].
Another example of rational drug dosage is evident in the
study from Laer et al. where population PK modelling and
simulations have been applied to develop age-based dosing
regimens for sotalol in children with supraventricular tachy-
cardia. For children<6 years the identified dose was higher
than the one for neonates and children>6 years [48].
M&S and personalised medicines
A CTS represents one of the most obvious methods of
exploring the concept of personalised medicine and its
implications in clinical practice. M&S techniques can be
applied to identify patient subgroups and tailor dosing
regimen for specific subsets of the population [14, 22].
PBPK-PD models, pop PK and pop PKPD models, as well
as disease models can all be used for this purpose [7, 19,
21, 27, 49]. The use of a model-based approach for
personalised medicines also permits better scrutiny of
diagnostic and prognostic factors, including quantitative
estimates of differences in the risk–benefit ratio for a given
group of patients or treatment option (Fig. 5). Despite the
Fig. 5 The concept of personalised medicines implies quantitative
assessment of the risk–benefit ratio at the individual and patient
population levels. M&S techniques are critical for such an evaluation.
The use of a therapeutic utility index (TUI) illustrates how the safety–
efficacy ratio of a treatment correlates with drug exposure. The graphs
show a safety: probability of a major or minor bleeding event as a
function of daily steady-state apixaban exposure (AUCss); b efficacy:
probability of a venous thromboembolic event (VTE) as a function of
daily apixaban AUCss and regimen. The shaded regions surrounding
the regression lines represent the 90% bootstrap confidence intervals.
The boxes at the bottom of each figure represent the distribution of
apixaban exposures for the doses indicated. Exposure distributions are
shown for the total daily dose (TDD) because the distributions of
AUCss should be the same for b.i.d. and q.d. regimens for the same
total daily dose. Subjects with moderate renal impairment are expected
to have a 43% increase in apixaban exposure; however, apixaban’s
therapeutic utility index suggests that dose adjustment is not needed in
this population. From Leil et al. [53]
Eur J Clin Pharmacol (2011) 67 (Suppl 1):S75–S86 S83natural role of CTS in this field, so far its use has been
relatively limited. Very few examples exist in which
personalisation of treatment has been based on clinical
relevance, rather than on pure scientific rationale. Recently,
Albers et al. used simulations to assess the implications of a
new age-based dosing strategy for carvedilol. The study
showed that higher doses in younger patients (with respect
to body weight) are needed to achieve the same exposure as
adults [50]. Likewise, a CTS has been used for diclofenac
as the basis for the evaluation of an effective and safe
dosing regimen for acute pain in children [51].
Albeit a constant theme in scientific and regulatory
forums, the use of personalised medicine concepts in
paediatric scenarios remains wishful thinking. Both the
FDA and the European regulatory authorities are increas-
ingly requesting risk–benefit analyses of medicines. How-
ever, such appeals are not accompanied by suggested
methods to be used in these analyses [52]. Furthermore, it
has not become clear to most stakeholders that empirical
methods are not suitable for the evaluation of multiple risk
and benefit criteria, in particular in the presence of
potential uncertainty because of the incompleteness of
the evidence. Moreover, experimental evidence does not
allow accurate assessment of the trade-offs of the benefits
against the risks.
It can be anticipated that empirical evaluation of so
many interacting factors cannot be defended without
serious ethical and scientific issues. M&S techniques are
critical enablers for the implementation of personalised
medicines and quantitative assessment of the risk–benefit
ratio at individual and patient population levels. The use of
a therapeutic utility index (TUI) illustrates such an
endeavour. The concept has been introduced to enable the
assessment of safety/efficacy of a treatment as a function of
exposure. Using a model-based approach, Leil et al. show
that renal impairment has no impact on efficacy/safety,
despite significant differences in drug exposure [53].
Conclusions
The recent changes in the legislation regarding paediatric
indications and the increasing understanding of the
mechanisms and pathophysiology of paediatric diseases
have created an unprecedented demand for evidence of
the therapeutic benefit of new treatments in children.
Such evidence cannot continue to be generated by
empirical methods. There are simply not enough patients
around to support drug development and approval
processes in the same way as they are currently handled
for adult indications. Moreover, even if availability of
patients were not an issue, practical and ethical aspects
cannot be overlooked.
Modelling and simulation can be used as a research
tool to provide answers regarding the efficacy and safety
of new drugs, in particular for paediatric and rare
diseases. Despite some technical challenges, its potential
value in paediatric research is indisputable and becomes
greater as more data are accumulated throughout the
development program. From a clinical and regulatory
perspective, optimal use of M&S may lead to fewer
study failures and a smaller number of studies needed for
generating the evidence required for the purposes of
registration. As indicated previously, regulatory authori-
ties have turned their interest towards the application of
M&S. However, to achieve the appropriate use of
medicines in children (reducing the burden of clinical
trials and improving efficacy and safety of therapeutic
treatments in this population) guidelines should be
implemented to recommend the proper use of M&S
techniques.
In conclusion, we have shown that M&S are valuable tools
for integrating and quantifying the interaction among drug,
disease and trial design factors. Although such clear-cut
results cannot be obtained by traditional research protocols,
M&S continuetoplaya small, supportiveroleinthe designof
empiricalclinicaltrials.Itcanbeanticipatedthat,inthefuture,
model-based approaches will become both the instrument and
the aim of drug development programs, yielding quantitative
evidence of the risk–benefit ratio for a given population or
dosing regimen without the burden of trial and error.
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